Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Ocugen said FDA granted Orphan Drug designation to OCU100 to treat retinitis pigmentosa. The company plans to start Phase I testing for OCU100, a recombinant PC4 and SFRS1-interacting protein ( PSIP1...